AUTHOR=Jayasinghe Thilini N. , Chiavaroli Valentina , Holland David J. , Cutfield Wayne S. , O'Sullivan Justin M. TITLE=The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation JOURNAL=Frontiers in Cellular and Infection Microbiology VOLUME=6 YEAR=2016 URL=https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2016.00015 DOI=10.3389/fcimb.2016.00015 ISSN=2235-2988 ABSTRACT=

Key Points

The microbiome has been implicated in the development of obesity.

Conventional therapeutic methods have limited effectiveness for the treatment of obesity and prevention of related complications.

Gut microbiome transplantation may represent an alternative and effective therapy for the treatment of obesity.

Obesity has reached epidemic proportions. Despite a better understanding of the underlying pathophysiology and growing treatment options, a significant proportion of obese patients do not respond to treatment. Recently, microbes residing in the human gastrointestinal tract have been found to act as an “endocrine” organ, whose composition and functionality may contribute to the development of obesity. Therefore, fecal/gut microbiome transplantation (GMT), which involves the transfer of feces from a healthy donor to a recipient, is increasingly drawing attention as a potential treatment for obesity. Currently the evidence for GMT effectiveness in the treatment of obesity is preliminary. Here, we summarize benefits, procedures, and issues associated with GMT, with a special focus on obesity.